¹⁸F-FLT and ¹⁸F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models

References

• Bading J R, Shields A F. Imaging of cell proliferation: status and prospects. Journal of Nuclear Medicine 2008; 49(2)64–80
   Web of Science ®Google Scholar
• Barthel H, Cleij M C, Collingridge D R, Hutchinson O C, Osman S, He Q, Luthra S K, Brady F, Price P M, Aboagye E O. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Research 2003; 63(13)3791–3798
   PubMed Web of Science ®Google Scholar
• Chen W S, Wei S J, Liu J M, Hsiao M, Kou-Lin J, Yang W K. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. International Journal of Cancer 2001; 91(6)894–899
   PubMed Web of Science ®Google Scholar
• Chinery R, Coffey R J, Graves-Deal R, Kirkland S C, Sanchez S C, Zackert W E, Oates J A, Morrow J D. Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Research 1999; 59(11)2739–2746
   PubMed Web of Science ®Google Scholar
• Davis T W, O'Neal J M, Pagel M D, Zweifel B S, Mehta P P, Heuvelman D M, Masferrer J L. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Research 2004; 64(1)279–285
   PubMed Web of Science ®Google Scholar
• Diaz A, Chepenik K P, Korn J H, Reginato A M, Jimenez S A. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Experimental Cell Research 1998; 241(1)222–229
   PubMed Web of Science ®Google Scholar
• Dittmann K H, Mayer C, Ohneseit P A, Raju U, Andratschke N H, Milas L, Rodemann H P. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: A COX-2 independent mechanism. International Journal of Radiation Oncology Biology Physics 2008; 70(1)203–212
   PubMed Web of Science ®Google Scholar
• Grosch S, Maier T J, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of National Cancer Institute 2006; 98(11)736–747
   PubMedGoogle Scholar
• Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, Evans J, O'Neill G. Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 1996; 111(2)445–454
   PubMed Web of Science ®Google Scholar
• Khan K N, Masferrer J L, Woerner B M, Soslow R, Koki A T. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scandinavion Journal of Gastroenterol 2001; 36(8)865–869
   PubMed Web of Science ®Google Scholar
• Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer J L, Tofilon P J, Milas L. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Research 2000; 60(5)1326–1331
   PubMed Web of Science ®Google Scholar
• Leahy K M, Koki A T, Masferrer J L. Role of cyclooxygenases in angiogenesis. Current Medicinal Chemistry 2000; 7(11)1163–1170
   PubMed Web of Science ®Google Scholar
• Leahy K M, Ornberg R L, Wang Y, Zweifel B S, Koki A T, Masferrer J L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Research 2002; 62(3)625–631
   PubMed Web of Science ®Google Scholar
• Leyton J, Alao J P, Da C M, Stavropoulou A V, Latigo J R, Perumal M, Pillai R, He Q, Atadja P, Lam E W, Workman P, Vigushin D M, Aboagye E O. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Cancer Research 2006; 66(15)7621–7629
   PubMed Web of Science ®Google Scholar
• Leyton J, Latigo J R, Perumal M, Dhaliwal H, He Q, Aboagye E O. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Research 2005; 65(10)4202–4210
   PubMed Web of Science ®Google Scholar
• Li G, Yang T, Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochemical and Biophysical Research Communications 2002; 299(5)886–890
   PubMed Web of Science ®Google Scholar
• Mankoff D A, Eary J F, Link J M, Muzi M, Rajendran J G, Spence A M, Krohn K A. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clinical Cancer Research 2007; 13(12)3460–3469
   PubMed Web of Science ®Google Scholar
• Mann M, Sheng H, Shao J, Williams C S, Pisacane P I, Sliwkowski M X, DuBois R N. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 2001; 120(7)1713–1719
   PubMed Web of Science ®Google Scholar
• Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors as potential enhancers of tumor radioresponse. Seminars in Radiation Oncology 2001; 11(4)290–299
   PubMed Web of Science ®Google Scholar
• Milas L, Kishi K, Hunter N, Mason K, Masferrer J L, Tofilon P J. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. Journal of the National Cancer Institute 1999; 91(17)1501–1504
   PubMed Web of Science ®Google Scholar
• Pyo H, Choy H, Amorino G P, Kim J S, Cao Q, Hercules S K, DuBois R N. A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clinical Cancer Research 2001; 7(10)2998–3005
   PubMed Web of Science ®Google Scholar
• Salskov A, Tammisetti V S, Grierson J, Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine. Seminars in Nuclear Medicine 2007; 37(6)429–439
   PubMed Web of Science ®Google Scholar
• Shao J, Sheng H, Inoue H, Morrow J D, DuBois R N. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. Journal of Biological Chemistry 2000; 275(43)33951–33956
   PubMed Web of Science ®Google Scholar
• Sheng H, Shao J, Morrow J D, Beauchamp R D, DuBois R N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Research 1998; 58(2)362–366
   PubMed Web of Science ®Google Scholar
• Shin Y K, Park J S, Kim H S, Jun H J, Kim G E, Suh C O, Yun Y S, Pyo H. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)- 2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Research 2005; 65(20)9501–9509
   PubMed Web of Science ®Google Scholar
• Sugiyama M, Sakahara H, Sato K, Harada N, Fukumoto D, Kakiuchi T, Hirano T, Kohno E, Tsukada H. Evaluation of 3′-deoxy-3′- 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. Journal of Nuclear Medicine 2004; 45(10)1754–1758
   PubMed Web of Science ®Google Scholar
• Tang X, Sun Y J, Half E, Kuo M T, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Research 2002; 62(17)4903–4908
   PubMed Web of Science ®Google Scholar
• Tazawa R, Xu X M, Wu K K, Wang L H. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochemical and Biophysical Research Communications 1994; 203(1)190–199
   PubMed Web of Science ®Google Scholar
• Tsujii M, Kawano S, DuBois R N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences of the USA 1997; 94(7)3336–3340
   PubMed Web of Science ®Google Scholar
• van Waarde A, Elsinga P H. Proliferation markers for the differential diagnosis of tumor and inflammation. Current Pharmaceutical Design 2008; 14(31)3326–3339
   PubMed Web of Science ®Google Scholar
• Zhao S, Kuge Y, Kohanawa M, Takahashi T, Zhao Y, Yi M, Kanegae K, Seki K, Tamaki N. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: A comparison with 18F-FDG and 18F-FLT. Journal of Nuclear Medicine 2008; 49(1)135–141
   PubMed Web of Science ®Google Scholar